drug
LYTGOBI
updated 3mo agoby Taiho Oncology Inc
community read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying LYTGOBI
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- phase2Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- phase3Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
- phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
- phase2Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
- phase2A Study of TAS-120 in Patients With Metastatic Breast Cancer
- phase2Futibatinib in Patients With Specific FGFR Aberrations
- phase3Personalized Medicine for Advanced Biliary Cancer Patients
News(1)
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 8d ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that